Pfizer Seeks Authorization of Covid-19 Vaccine
After lots of speculation and anticipation for a coronavirus vaccine, Pfizer is planning to ask U.S. health regulators on Friday to approve use of it and its partner, BioNTech SE’s Covid-19 vaccine. This is after months of research and effort to find a solution to mitigate and reduce the coronavirus pandemic. Dr. Albert Bourla, Pfizer chairman and CEO, said, “Our work to deliver a safe and effective vaccine has never been more urgent, as we continue to see an alarming rise in the number of cases of COVID-19 globally…"
Moderna, another drug maker developing a vaccine, is also expected to file for emergency use within the next few weeks. Due to the urgency of the situation, the FDA is expected to act quickly. The filing of the vaccine approval is in line with government projections, with Pfizer saying the filing could allow for distribution to begin by the middle to end of December. Going from laboratory to authorization in less than a year if approved, this will be the fastest vaccine development program in the West, representing unprecedented advancement in medical technology.
• On track for December distribution
• 95% effective in 44,000-person trial
• FDA will determine safety and approval before possible distribution when company files
• Two-shot vaccine, given three week apart